Adezmapimod (Standard)

Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator[1][2][3].

Product Specifications

CAS Number

[152121-47-6]

Product Name Alternative

SB 203580 (Standard) ; RWJ 64809 (Standard)

UNSPSC

12352005

Target

Autophagy; HSP; Mitophagy; Organoid; p38 MAPK; Reference Standards

Related Pathways

Autophagy; Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/Wnt

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=S(C1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1)C

Molecular Formula

C21H16FN3OS

Molecular Weight

377.43

References & Citations

[1]Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351 (Pt 1) :95-105.|[2]Lali FV, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000 Mar 10;275 (10) :7395-402.|[3]Leelahavanichkul K, et al. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol. 2014 Feb;8 (1) :105-18.